Santaris Pharma
Biopharmaceutical company focused on the discovery and development of rna-targeted therapies
At a glance
- Founded
- 2003
- Headquarters
- Hørsholm, Denmark
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later13 investors entered at this stage
- GHGilde Healthcare
- TETeknoinvest
Heartcore Capital- GVGlobal Life Science Ventures
- DEDansk Erhvervsinvestering
- LPLD Pensions
- ABABN AMRO Life Capital Belgium
- ICInnovation Capital
- OFOmega Funds
- FPForbion Capital Partners
- SPSeventure Partners
- BABankInvest
- NHNovo Holdings
Ownership
Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.
“Other / undisclosed” is the 5% not attributed to a named shareholder. See the full cap table on Dealroom →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Santaris Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Santaris Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.